The global organ on a chip market size was estimated to be USD 0.229 billion in 2023 and is expected to reach at USD 4.53 billion by 2034 with a CAGR of 31.16% during the forecast period 2024-2034. Rising demand for alternatives to animal testing, the necessity for early detection of drug toxicity, the emergence of new product launches, growing technological advancements, increasing demand for personalized medication, surge in investment in healthcare research, rising demand for drug screening, growing interest for lung-based organ culture & applications related to the kidney, rise in the number of chronic diseases, and increasing introduction of new products used for organ on a chip are some of the key factors boosting the market growth.
Increasing introduction of new products used for organ on a chip is predicted to boost the market growth during the forecast period. An organ-on-a-chip is a microfluidic cell culture device that includes continuously perfused chambers. This chip creates a narrow channel to mimic the flow of blood and air in organs like the lung, gut, liver, heart, and others. These devices can replicate multiple levels of tissue and organ functions, which cannot be achieved with traditional 2D and 3D culture systems. They have a wide range of applications, including disease modeling, patient stratification, and phenotypic screening. For instance, in April 2023, BIO INX, a Belgian start-up specializing in ink development for various applications, including bioprinting and 3D printing, has introduced a new resin suitable for 3D printing organ-on-chips. This new resin, known as Hydrotech INX N200, is a biocompatible hydrogel resin designed for two-photon polymerization (2PP).
By organ type, lung was the highest revenue-grossing segment in the global organ on a chip market in 2023 owing to the decreased availability of lung transplantations has prompted the development of laboratory-engineered chips that replicate lung functions, facilitating drug screening for respiratory disorders, growing emphasis on the creation of innovative remedies for the treatment of pulmonary diseases, and surge in incidence of pulmonary diseases such as tuberculosis. Additionally, heart-on-chip is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of cardiovascular disorders, increasing research & development activities for different approaches to treating the disorder, and surge in mergers & acquisitions within market players. For instance, in April 2022, Valo Health has acquired TARA Biosystems, the creators of a 3D heart tissue modeling platform. Valo intends to integrate TARA's heart tissue chips into their comprehensive drug development solution focused on cardiovascular disease, powered by their Opal data platform.
By application, drug discovery was the highest revenue-grossing segment in the global organ on a chip market in 2023 owing to the pharmaceutical sector encounters several challenges due to the increasing expenses and declining efficiency of drug research and development, increasing need for novel testing methods to generate precise predictions regarding drug safety & efficacy, and rising launch of new products. For instance, in March 2023, MIMETAS, a prominent company in the Netherlands specializing in organ-on-chip technology for disease modeling, has revealed the introduction of its Adult Stem Cell (ASC)-derived tubular organoids in a format ready for assays. This development is part of their OrganoReady product line. Additionally, toxicology research is predicted to grow at fastest CAGR during the forecast period owing to the emerging laws and regulations are shaping the landscape of drug safety and chemical testing, increasing use of Organ-on-a-Chip (OoC) technology is being employed for innovative phenotypic screening assays and the development of cost-effective in-vitro models for hit-to-lead and lead optimization. These models have the capability to offer more precise predictions of drug compounds' efficacy, toxicity, and human pharmacokinetics. Technological advancements are enhancing our comprehension of the detrimental health impacts of toxic substances.
By end-user, pharmaceutical and biotechnology companies was the highest revenue-grossing segment in the global organ on a chip market in 2023 owing to the numerous pharmaceutical & biotechnology firms are leveraging this technology to expedite the discovery and advancement of new pharmaceuticals, the heightened utilization of Organ-on-a-Chip technology for drug discovery within the business sector, rising public awareness regarding organs-on-chips and the amplified emphasis of major corporations on research and development (R&D) endeavors, and growing launch of new products. For instance, in June 2023, Emulate has introduced the Emulate Chip-A1 with the aim of expanding its applications in the fields of cancer research and the cosmetic industry. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the prominent research institutions with a specialization in organ-on-chip technologies.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing spending on research for drug discovery & biotechnology, a broad spectrum of services provided by major industry players, including tailored design of new chips with specific organ configurations, and rising focus on the development of new therapies. For instance, in September 2022, Emulate has unveiled a novel gene therapy application that harnesses Organ-on-a-Chip technology to expedite the development of therapies for genetic diseases. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in the toxicological testing of chemicals on various types of organ cells, significant investments are being allocated by both public and private institutions for their research endeavors, numerous initiatives are being undertaken to offer organ-on-chip services. For instance, in May 2022, Nikon Instruments Inc., based in the United States, has announced its plans to commence organ-on-a-chip imaging and analysis contract services in an efficient manner to support research and development in the field of drug discovery.
Increasing introduction of new products used for organ on a chip is predicted to boost the market growth during the forecast period. An organ-on-a-chip is a microfluidic cell culture device that includes continuously perfused chambers. This chip creates a narrow channel to mimic the flow of blood and air in organs like the lung, gut, liver, heart, and others. These devices can replicate multiple levels of tissue and organ functions, which cannot be achieved with traditional 2D and 3D culture systems. They have a wide range of applications, including disease modeling, patient stratification, and phenotypic screening. For instance, in April 2023, BIO INX, a Belgian start-up specializing in ink development for various applications, including bioprinting and 3D printing, has introduced a new resin suitable for 3D printing organ-on-chips. This new resin, known as Hydrotech INX N200, is a biocompatible hydrogel resin designed for two-photon polymerization (2PP).
By organ type, lung was the highest revenue-grossing segment in the global organ on a chip market in 2023 owing to the decreased availability of lung transplantations has prompted the development of laboratory-engineered chips that replicate lung functions, facilitating drug screening for respiratory disorders, growing emphasis on the creation of innovative remedies for the treatment of pulmonary diseases, and surge in incidence of pulmonary diseases such as tuberculosis. Additionally, heart-on-chip is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of cardiovascular disorders, increasing research & development activities for different approaches to treating the disorder, and surge in mergers & acquisitions within market players. For instance, in April 2022, Valo Health has acquired TARA Biosystems, the creators of a 3D heart tissue modeling platform. Valo intends to integrate TARA's heart tissue chips into their comprehensive drug development solution focused on cardiovascular disease, powered by their Opal data platform.
By application, drug discovery was the highest revenue-grossing segment in the global organ on a chip market in 2023 owing to the pharmaceutical sector encounters several challenges due to the increasing expenses and declining efficiency of drug research and development, increasing need for novel testing methods to generate precise predictions regarding drug safety & efficacy, and rising launch of new products. For instance, in March 2023, MIMETAS, a prominent company in the Netherlands specializing in organ-on-chip technology for disease modeling, has revealed the introduction of its Adult Stem Cell (ASC)-derived tubular organoids in a format ready for assays. This development is part of their OrganoReady product line. Additionally, toxicology research is predicted to grow at fastest CAGR during the forecast period owing to the emerging laws and regulations are shaping the landscape of drug safety and chemical testing, increasing use of Organ-on-a-Chip (OoC) technology is being employed for innovative phenotypic screening assays and the development of cost-effective in-vitro models for hit-to-lead and lead optimization. These models have the capability to offer more precise predictions of drug compounds' efficacy, toxicity, and human pharmacokinetics. Technological advancements are enhancing our comprehension of the detrimental health impacts of toxic substances.
By end-user, pharmaceutical and biotechnology companies was the highest revenue-grossing segment in the global organ on a chip market in 2023 owing to the numerous pharmaceutical & biotechnology firms are leveraging this technology to expedite the discovery and advancement of new pharmaceuticals, the heightened utilization of Organ-on-a-Chip technology for drug discovery within the business sector, rising public awareness regarding organs-on-chips and the amplified emphasis of major corporations on research and development (R&D) endeavors, and growing launch of new products. For instance, in June 2023, Emulate has introduced the Emulate Chip-A1 with the aim of expanding its applications in the fields of cancer research and the cosmetic industry. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the prominent research institutions with a specialization in organ-on-chip technologies.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing spending on research for drug discovery & biotechnology, a broad spectrum of services provided by major industry players, including tailored design of new chips with specific organ configurations, and rising focus on the development of new therapies. For instance, in September 2022, Emulate has unveiled a novel gene therapy application that harnesses Organ-on-a-Chip technology to expedite the development of therapies for genetic diseases. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in the toxicological testing of chemicals on various types of organ cells, significant investments are being allocated by both public and private institutions for their research endeavors, numerous initiatives are being undertaken to offer organ-on-chip services. For instance, in May 2022, Nikon Instruments Inc., based in the United States, has announced its plans to commence organ-on-a-chip imaging and analysis contract services in an efficient manner to support research and development in the field of drug discovery.
Segmentation: Organ On A Chip Market Report 2023 - 2034
Organ On A Chip Market Analysis & Forecast by Organ Type 2023 - 2034 (Revenue USD Bn)
- Heart
- Lung
- Liver
- Other
Organ On A Chip Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Toxicology Research
- Drug Discovery
- Others
Organ On A Chip Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Other
Organ On A Chip Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Organ On A Chip Market: Organ Type Estimates & Trend Analysis
8. Organ On A Chip Market: Application Estimates & Trend Analysis
9. Organ On A Chip Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Organ On A Chip Market
12. Europe Global Organ On A Chip Market
13. Asia Pacific Global Organ On A Chip Market
14. Latin America Global Organ On A Chip Market
15. MEA Global Organ On A Chip Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- CN Bio Innovations Limited
- Emulate Inc.
- Mimetas B.V.
- Tara Biosystems
- AxoSim Technologies LLC
- Elveflow
- Nortis Inc.
- Insphero AG
- BICO Group AB(Visikol)
- Organovo Holdings Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.23 Billion |
| Forecasted Market Value ( USD | $ 4.53 Billion |
| Compound Annual Growth Rate | 31.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
